Table 2.

Multivariate analysis of the number of relapses at 1 year

Variable	Coefficient [95% CI]†	p value
Treatment (ocrelizumab versus fingolimod)	− 0.264 [− 0.510; − 0.0489]	0.035
Sex (male versus female)	− 0.128 [− 0.363; 0.109]	0.3
Age	− 0.00484 [− 0.0202; 0.0107]	0.5
Disease duration	− 0.00758 [− 0.0309; 0.0108]	0.5
Time with NTZ	0.00150 [− 0.00721; 0.0108]	0.8
Number of relapses the year before NTZ cessation	− 0.0303 [− 0.241; 0.290]	0.8
Baseline EDSS (+ 0.1)	0.00921 [0.00335; 0.0174]	0.019
Presence of infratentorial lesion in the last brain MRI (no versus yes)	0.0647 [− 0.218; 0.420]	0.6

CI confidence interval, EDSS  Expanded Disability Status Scale, NTZ natalizumab

^† Multivariate linear regression model